02:16 , Nov 12, 2014 |  BC Extra  |  Company News

Ascletis gets China license for Presidio HCV candidate

Presidio Pharmaceuticals Inc. (San Francisco, Calif.) granted Ascletis Pharmaceuticals Co. Ltd. (Hangzhou, China) exclusive development and commercialization rights to HCV candidate PPI-668 in China, Taiwan, Hong Kong and Macau. Presidio received an undisclosed upfront payment...
07:00 , May 6, 2013 |  BC Week In Review  |  Company News

Ascletis, J&J deal

Johnson & Johnson's Janssen R&D Ireland unit granted Ascletis exclusive rights to develop and commercialize Janssen's HIV compound TMC310911 in China. J&J is eligible for undisclosed royalties based on Chinese sales of the HIV protease...
00:39 , May 1, 2013 |  BC Extra  |  Company News

J&J grants Ascletis Chinese rights to HIV candidate

The Janssen R&D Ireland unit of Johnson & Johnson (NYSE:JNJ) granted Ascletis Pharmaceuticals Co. Ltd. (Hangzhou, China) exclusive, Chinese rights to develop and commercialize Janssen's HIV compound TMC310911. J&J is eligible for undisclosed royalties based...